Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 782, 2004; 10.1373/clinchem.2003.024596
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwan, R.
Right arrow Articles by Llorca, P.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwan, R.
Right arrow Articles by Llorca, P.M.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 2004;50:782.)
© 2004 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Which Types of Alcohol-Use Disorder Will Asialotransferrin Detect?

Raymund Schwan1,a, L. Malet1, M.N. Loiseaux2 and P.M. Llorca1

1 Department of Psychiatry, University Hospital, Clermont-Ferrand, France
2 Biochemistry Department, General Hospital, Moulins, France

aAddress correspondence to this author at: Centre Médico-Psychologique-B, Rue Montalembert, F-63003 Clermont-Ferrand Cedex 1, France. Fax 33-4-7375-2074; e-mail rschwan@chu-clermontferrand.fr.

The first 20% of the full text of this article appears below.


To the Editor:

Approximately 20% of patients seen in clinical practice have an underlying alcohol-use disorder (1). In the last 20 years, specialist work on alcohol misuse has focused mainly on diagnosis at the dependence stage. However, there is also a need to direct attention to alcohol abuse, the long, little-studied, and insufficiently treated disease during which processes damaging to health and social functioning are initiated. Recently, Legros et al. (2) concluded that as a biomarker, asialotransferrin offered the best differentiation between moderate and abusive alcohol consumption.

From a methodologic point of view, clinical investigations concerning biomarkers of alcohol abuse or . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.